Evidence map›Paper›PMID 41329317›Full record

ArticleInternational journal of hematology2026

Distinct immunophenotypic profiles of circulating tumor plasma cells in MGUS and smoldering multiple myeloma.

Atsushi Uehara, Kentaro Narita, Fuminari Fujii, Hajime Sakuma, Mitsuaki Oura, Masanori Toho, Daisuke Ikeda, Rikako Tabata, Masami Takeuchi, Kosei Matsue

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Atsushi UeharaDivision of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-Chou, Kamogawa-Shi, Chiba, 296-8602, Japan.
Kentaro NaritaDivision of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-Chou, Kamogawa-Shi, Chiba, 296-8602, Japan.
Fuminari FujiiDivision of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-Chou, Kamogawa-Shi, Chiba, 296-8602, Japan.
Hajime SakumaDivision of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-Chou, Kamogawa-Shi, Chiba, 296-8602, Japan.
Mitsuaki OuraDivision of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-Chou, Kamogawa-Shi, Chiba, 296-8602, Japan.
Masanori TohoDivision of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-Chou, Kamogawa-Shi, Chiba, 296-8602, Japan.
Daisuke IkedaDivision of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-Chou, Kamogawa-Shi, Chiba, 296-8602, Japan.
Rikako TabataDivision of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-Chou, Kamogawa-Shi, Chiba, 296-8602, Japan.
Masami TakeuchiDivision of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-Chou, Kamogawa-Shi, Chiba, 296-8602, Japan.
Kosei MatsueDivision of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-Chou, Kamogawa-Shi, Chiba, 296-8602, Japan. koseimatsue@gmail.com.ORCID http://orcid.org/0000-0002-8669-9865

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study characterized the phenotypic and cytogenetic features of circulating tumor plasma cells (CTPCs) in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). A total of 120 patients were analyzed (MGUS, n = 70; SMM, n = 50). CTPCs were detected in 38.2% of MGUS and 61.8% of SMM. Immunophenotypic analysis based on mean fluorescence intensity revealed that CD200, CD117, CD38, CD56, and CD28 were significantly downregulated and CD45 was significantly overexpressed in CTPCs compared with BMPCs, whereas CD138 and CD81 expression levels did not differ. Cytogenetic analysis demonstrated higher prevalence of del(13q) and high-risk chromosomal abnormalities in CTPC-positive patients than CTPC-negative patients (24.0% vs. 4.5%, p = 0.048; 26.5% vs. 7.0%, p = 0.011, respectively). No significant differences were observed in other cytogenetic abnormalities including 1q gain/amplification, t(4;14), t(11;14), t(14;16), or del(17p). Serum soluble B cell maturation antigen levels did not differ between patients with or without detectable CTPCs in MGUS or SMM. These findings highlight the distinct phenotypic and cytogenetic characteristics of CTPCs in MGUS and SMM, and provide insights regarding their biological features and pathogenesis.

Indexed as

Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaNeoplastic Cells, CirculatingPlasma CellsSmoldering Multiple MyelomaAdultAgedAged, 80 and overAntigens, CDChromosome AberrationsFemaleHumansImmunophenotypingMaleMiddle AgedAntigens, CDCirculating tumor plasma cellsMonoclonal gammopathy of undetermined significanceSmoldering multiple myeloma

Identifiers

PMID41329317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.